{
"ranked_hypotheses": [
{
"rank": 1,
"title": "FYN Kinase-Mediated Synaptic Signaling Cascade",
"mechanism": "Aβ oligomers activate FYN kinase at the postsynaptic density, which phosphorylates both NMDA receptors (enhancing excitotoxicity) and tau (promoting missorting), creating a pathogenic feedforward loop that persists independent of Aβ burden.",
"target_gene": "FYN",
"confidence_score": 0.6,
"novelty_score": 0.7,
"feasibility_score": 0.7,
"impact_score": 0.9,
"composite_score": 0.70,
"testable_prediction": "FYN knockout or pharmacological inhibition in 5xFAD mice will block tau missorting to dendrites even when Aβ accumulation continues unchanged.",
"skeptic_concern": "Causal direction ambiguous—FYN activation could be downstream consequence rather than driver of Aβ toxicity."
},
{
"rank": 2,
"title": "Kinase-Phosphatase Set-Point Disruption",
"mechanism": "Aβ burden shifts the kinase/phosphatase equilibrium toward tau hyperphosphorylation by simultaneously upregulating GSK3β/CDK5 activity and downregulating PP2A function, locking tau into a pathogenic phosphorylation state.",
"target_gene": "GSK3B",
"confidence_score": 0.7,
"novelty_score": 0.5,
"feasibility_score": 0.7,
"impact_score": 0.8,
"composite_score": 0.68,
"testable_prediction": "Sustained PP2A activation in Aβ-producing mice will prevent formation of hyperphosphorylated tau oligomers despite ongoing amyloid deposition.",
"skeptic_concern": "Redundancy among tau kinases may limit therapeutic efficacy of single-target inhibitors."
},
{
"rank": 3,
"title": "Prion-Like Cross-Seeding via Oligomer Interfaces",
"mechanism": "Aβ*56 oligomers expose cryptic β-strand domains that template tau R2/R3 repeat domain conversion into β-sheet-rich nuclei, bypassing homogeneous nucleation and explaining the temporal sequence of Aβ preceding tau spreading.",
"target_gene": "None",
"confidence_score": 0.5,
"novelty_score": 0.6,
"feasibility_score": 0.4,
"impact_score": 0.8,
"composite_score": 0.58,
"testable_prediction": "Co-immunoprecipitation of Aβ*56 with misfolded tau species from human AD brain tissue will demonstrate stable physical interaction absent from age-matched controls.",
"skeptic_concern": "Structural basis for the claimed interface remains uncharacterized; in vitro cross-seeding requires non-physiological concentrations."
}
],
"consensus_points": [
"Aβ-tau synergy is necessary to explain both Alzheimer's disease progression and anti-Aβ trial failures",
"Tau pathology is downstream of Aβ but becomes self-propagating and Aβ-independent",
"Multi-target approaches will likely outperform monotherapies targeting either protein in isolation"
],
"dissent_points": [
"Timing windows differ by mechanism—cross-seeding may require intervention before Aβ accumulation, while kinase/phosphatase disruption could work post-symptomatically"
],
"debate_summary": "The debate converges on Aβ-tau synergy as the critical pathogenic mechanism explaining why amyloid-targeting monotherapies fail, with expert ranking favoring downstream effector pathways (FYN signaling, kinase-phosphatase imbalance) over upstream nucleation events due to superior translational potential and broader therapeutic windows. The prion-like cross-seeding hypothesis remains mechanistically compelling but faces structural validation challenges that limit near-term clinical translation."
}